(Q87135143)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Zhiguang Zhou

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Lin Yang

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Xiangbing Wang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

1 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

Diabetes - Metabolism: Research and Reviews

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

646-653

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

Biology of incretins: GLP-1 and GIP

5 March 2020

cites work

1 reference

7 January 2021

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

7 January 2021

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

7 January 2021

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance

1 reference

7 January 2021

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

1 reference

7 January 2021

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

1 reference

7 January 2021

Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.

1 reference

7 January 2021

Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice

1 reference

7 January 2021

Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells

1 reference

7 January 2021

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

7 January 2021

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

1 reference

7 January 2021

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor

1 reference

7 January 2021

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation

1 reference

7 January 2021

The pathogenesis of insulin-dependent diabetes mellitus

1 reference

7 January 2021

Transfer of diabetes in the NOD-scid mouse by CD4 T-cell clones. Differential requirement for CD8 T-cells

1 reference

7 January 2021

Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies

1 reference

7 January 2021

Helper T cell diversity and plasticity

1 reference

7 January 2021

Insulitis in type 1 (insulin-dependent) diabetes mellitus in man--macrophages, lymphocytes, and interferon-gamma containing cells

1 reference

7 January 2021

Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice

1 reference

7 January 2021

Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation?

1 reference

7 January 2021

Immunology: T cells hang in the balance

1 reference

7 January 2021

Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

1 reference

7 January 2021

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

1 reference

7 January 2021

Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children

1 reference

7 January 2021

IL-17 immunity in human type 1 diabetes

1 reference

7 January 2021

Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice.

1 reference

7 January 2021

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

1 reference

7 January 2021

Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice

1 reference

7 January 2021

A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus.

1 reference

7 January 2021

Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes

1 reference

7 January 2021

Direct association of adenosine deaminase with a T cell activation antigen, CD26

1 reference

7 January 2021

Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets

1 reference

7 January 2021

Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells

1 reference

7 January 2021

Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26)

1 reference

7 January 2021

Functional role of CD26 on human B lymphocytes

1 reference

7 January 2021

A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation

1 reference

7 January 2021

Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function

1 reference

7 January 2021

The structure and function of CD26 in the T-cell immune response

1 reference

7 January 2021

In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

1 reference

7 January 2021

Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo

1 reference

7 January 2021

Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients

1 reference

7 January 2021

T-cell immune parameters and depression in patients with Crohn's disease.

1 reference

7 January 2021

Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones.

1 reference

7 January 2021

DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis

1 reference

7 January 2021

CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis

1 reference

7 January 2021

CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry

1 reference

7 January 2021

Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13)--a novel approach for the treatment of inflammatory bowel disease.

1 reference

7 January 2021

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

1 reference

7 January 2021

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

1 reference

7 January 2021

Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition

1 reference

7 January 2021

MECHANISMS OF CD26/DIPEPTIDYL PEPTIDASE IV CYTOKINE-DEPENDENT REGULATION ON HUMAN ACTIVATED LYMPHOCYTES

1 reference

7 January 2021

Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.

1 reference

7 January 2021

Enhanced ovalbumin-induced airway inflammation in CD26−/−mice

1 reference

7 January 2021

Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions

1 reference

7 January 2021

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

1 reference

7 January 2021

Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease

1 reference

7 January 2021

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

1 reference

7 January 2021

TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes

1 reference

7 January 2021

TGF-beta signaling is required for the function of insulin-reactive T regulatory cells

1 reference

7 January 2021

Transforming growth factor-beta regulation of immune responses

1 reference

7 January 2021

Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells

1 reference

7 January 2021

Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins

1 reference

7 January 2021

TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26

1 reference

7 January 2021

Th17: an effector CD4 T cell lineage with regulatory T cell ties

1 reference

7 January 2021

T(H)-17 cells in the circle of immunity and autoimmunity

1 reference

7 January 2021

CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production

1 reference

7 January 2021

Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.

1 reference

7 January 2021

CD26, let it cut or cut it down.

1 reference

7 January 2021

CD26 is expressed on a restricted subpopulation of dendritic cells in vivo

1 reference

7 January 2021

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

1 reference

7 January 2021

Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production.

1 reference

7 January 2021

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

1 reference

7 January 2021

Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways

1 reference

7 January 2021

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice

1 reference

7 January 2021

Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series

1 reference

7 January 2021

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial

1 reference

7 January 2021

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

1 reference

7 January 2021

Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.2530

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446278%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference